Table 1 Correlation between SH3RF2 expression levels and clinicopathological parameters of OC patients.
From: SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation
Clinical parameters | Cases | SH3RF2 expression levels | p value | |
---|---|---|---|---|
High | Low | |||
Overall | 120 | 61 | 59 | Â |
Age | Â | Â | Â | 0.2031a |
 ≤55 | 62 | 35 | 27 |  |
 >55 | 58 | 26 | 32 |  |
FIGO stage | Â | Â | Â | 0.2716a |
 I-II | 18 | 7 | 11 |  |
 III-IV | 102 | 54 | 48 |  |
Tumor size | Â | Â | Â | <0.05a |
 ≤7 cm | 66 | 28 | 38 |  |
 >7 cm | 54 | 33 | 21 |  |
Metastasis | Â | Â | Â | 0.3029a |
 Positive | 98 | 52 | 46 |  |
 Negative | 22 | 9 | 13 |  |
Grading | Â | Â | Â | 0.4561b |
 High-grade | 111 | 58 | 53 |  |
 Low-grade | 9 | 3 | 6 |  |
Subtype | Â | Â | Â | 0.8269a |
 Serous | 98 | 51 | 47 |  |
 Mucinous | 6 | 3 | 3 |  |
 Others | 16 | 7 | 9 |  |
DDP-based chemotherapy | Â | Â | Â | <0.0001a |
 DDP resistant | 61 | 46 | 15 |  |
 DDP sensitive | 59 | 15 | 44 |  |